Literature DB >> 10654103

Investigations on oxidative stress and therapeutical implications in dementia.

N Durany1, G Münch, T Michel, P Riederer.   

Abstract

Alzheimer's disease (AD) is a progressive dementia affecting a large proportion of the aging population. The histopathological changes in AD include neuronal cell death and formation of amyloid plaques and neurofibrillary tangles (NFTs) NFTs are composed of hyperphosphorylated tau protein, and senile plaques contain aggregates of the beta-peptide. There is also evidence that brain tissue in patients with AD is exposed to oxidative stress during the course of the disease. Advanced glycation endproducts (AGEs), which are formed by a non-enzymatic reaction of glucose with long-lived protein deposits, are potentially toxic to the cell, are present in brain plaques in AD, and its extracellular accumulation in AD may be caused by an accelerated oxidation of glycated proteins. The microtubuli-associated protein tau is also subject to intracellular AGE formation. AGEs participate in neuronal death causing direct (chemical) radical production: Glycated proteins produce nearly 50-fold more radicals than non-glycated proteins, and indirect (cellular) radical production: Interaction of AGEs with cells increases oxidative stress. During aging cellular defence mechanisms weaken and the damages to cell constituents accumulate leading to loss of function and finally cell death. The development of drugs for the treatment of AD remains at a very unsatisfying state. However, pharmacological approaches which break the vicious cycles of oxidative stress and neurodegeneration offer new opportunities for the treatment of AD. Theses approaches include AGE-inhibitors, antioxidants, and anti-inflammatory substances, which prevent radical production. AGE inhibitors might be able to stop formation of AGE-modified beta-amyloid deposits, antioxidants are likely to scavenge intracellular and extracellular superoxide radicals and hydrogen peroxide before these radicals damage cell constituents or activate microglia, and anti-inflammatory drugs attenuating microglial radical and cytokine production.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10654103     DOI: 10.1007/pl00014177

Source DB:  PubMed          Journal:  Eur Arch Psychiatry Clin Neurosci        ISSN: 0940-1334            Impact factor:   5.270


  15 in total

1.  [Neurodegeneration and neuroprotection].

Authors:  K-G Schmidt
Journal:  Ophthalmologe       Date:  2004-11       Impact factor: 1.059

Review 2.  Role of RAGE in Alzheimer's Disease.

Authors:  Zhiyou Cai; Nannuan Liu; Chuanling Wang; Biyong Qin; Yingjun Zhou; Ming Xiao; Liying Chang; Liang-Jun Yan; Bin Zhao
Journal:  Cell Mol Neurobiol       Date:  2015-07-15       Impact factor: 5.046

3.  Dysregulation of Intracellular Ca2+ in Dystrophic Cortical and Hippocampal Neurons.

Authors:  José R Lopez; Juan Kolster; Arkady Uryash; Eric Estève; Francisco Altamirano; José A Adams
Journal:  Mol Neurobiol       Date:  2016-12-15       Impact factor: 5.590

Review 4.  Targeting Inflammatory Pathways in Alzheimer's Disease: A Focus on Natural Products and Phytomedicines.

Authors:  Matthew J Sharman; Giuseppe Verdile; Shanmugam Kirubakaran; Cristina Parenti; Ahilya Singh; Georgina Watt; Tim Karl; Dennis Chang; Chun Guang Li; Gerald Münch
Journal:  CNS Drugs       Date:  2019-05       Impact factor: 5.749

5.  Protective role of S-nitrosoglutathione (GSNO) against cognitive impairment in rat model of chronic cerebral hypoperfusion.

Authors:  Je-Seong Won; Jinsu Kim; Balasubramaniam Annamalai; Anandakumar Shunmugavel; Inderjit Singh; Avtar K Singh
Journal:  J Alzheimers Dis       Date:  2013       Impact factor: 4.472

Review 6.  Oxidative stress in Alzheimer disease.

Authors:  Alejandro Gella; Nuria Durany
Journal:  Cell Adh Migr       Date:  2009-01-13       Impact factor: 3.405

7.  Central nervous system involvement in the animal model of myodystrophy.

Authors:  Clarissa M Comim; Bruna P Mendonça; Diogo Dominguini; Andreza L Cipriano; Amanda V Steckert; Giselli Scaini; Mariz Vainzof; Emílio L Streck; Felipe Dal-Pizzol; João Quevedo
Journal:  Mol Neurobiol       Date:  2013-03-19       Impact factor: 5.590

8.  Involvement of Maillard reactions in Alzheimer disease.

Authors:  V Prakash Reddy; Mark E Obrenovich; Craig S Atwood; George Perry; Mark A Smith
Journal:  Neurotox Res       Date:  2002-05       Impact factor: 3.911

9.  Coenzyme Q10 attenuates beta-amyloid pathology in the aged transgenic mice with Alzheimer presenilin 1 mutation.

Authors:  Xifei Yang; Ying Yang; Geng Li; Jianzhi Wang; Edward S Yang
Journal:  J Mol Neurosci       Date:  2008-01-05       Impact factor: 3.444

Review 10.  Gut Microbiota Composition and Epigenetic Molecular Changes Connected to the Pathogenesis of Alzheimer's Disease.

Authors:  Priyanka Nagu; Arun Parashar; Tapan Behl; Vineet Mehta
Journal:  J Mol Neurosci       Date:  2021-04-08       Impact factor: 3.444

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.